CCR5 is involved in resolution of inflammation in proteoglycan-induced arthritis
Article first published online: 29 SEP 2009
Copyright © 2009 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 60, Issue 10, pages 2945–2953, October 2009
How to Cite
Doodes, P. D., Cao, Y., Hamel, K. M., Wang, Y., Rodeghero, R. L., Kobezda, T. and Finnegan, A. (2009), CCR5 is involved in resolution of inflammation in proteoglycan-induced arthritis. Arthritis & Rheumatism, 60: 2945–2953. doi: 10.1002/art.24842
- Issue published online: 29 SEP 2009
- Article first published online: 29 SEP 2009
- Manuscript Accepted: 23 JUN 2009
- Manuscript Received: 11 FEB 2009
- NIH. Grant Number: AR-045652
CCR5 and its ligands (CCL3, CCL4, and CCL5) may play a role in inflammatory cell recruitment into the joint. However, it was recently reported that CCR5 on T cells and neutrophils acts as a decoy receptor for CCL3 and CCL5 to assist in the resolution of inflammation. The aim of this study was to determine whether CCR5 functions as a proinflammatory or antiinflammatory mediator in arthritis, by examining the role of CCR5 in proteoglycan (PG)–induced arthritis (PGIA).
Arthritis was induced by immunizing wild-type (WT) and CCR5-deficient (CCR5−/−) BALB/c mice with human PG in adjuvant. The onset and severity of PGIA were monitored over time. Met-RANTES was used to block CCR5 in vivo. Arthritis was transferred to SCID mice, using spleen cells from arthritic WT and CCR5−/− mice. The expression of cytokines and chemokines was measured by enzyme-linked immunosorbent assay.
In CCR5−/− mice and WT mice treated with the CCR5 inhibitor Met-RANTES, exacerbated arthritis developed late in the disease course. The increase in arthritis severity in CCR5−/− mice correlated with elevated serum levels of CCL5. However, exacerbated arthritis was not intrinsic to the CCR5−/− lymphoid cells, because the arthritis that developed in SCID mouse recipients was similar to that in WT and CCR5−/− mice. CCR5 expression in the SCID mouse was sufficient to clear CCL5, because serum levels of CCL5 were the same in SCID mouse recipients receiving cells from either WT or CCR5−/− mice.
These data demonstrate that CCR5 is a key player in controlling the resolution of inflammation in experimental arthritis.